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Introduction 
 
There is convincing evidence from animal and human studies that myocardial fibrosis 
of the left atrium (LA) and/or the left ventricle (LV), is involved in the 
pathophysiology of atrial fibrillation (AF). The the role of LA fibrosis in particular is of 
interest as a possible target for identification of patients more likely to benefit from 
rhythm control strategies including ablation. 1-5 A number of methods of quantifying 
such fibrosis are available, including imaging techniques such as cardiovascular 
magnetic resonance imaging (CMRI) and echocardiography, and minimally invasive 
electrophysiological (EP) mapping. The role of circulating biochemical markers is also 
the subject of interest for predicting successful rhythm control, and numerous 
potential biomarkers have been studied, with mixed results. 
 
In the context of catheter ablation of AF, the majority of studies assessing fibrosis 
biomarkers have tested peripheral levels. There is an assumption that peripheral 
levels of biomarkers will match intra-cardiac levels. However, this assumption has 
not been conclusively tested, so it is not clear whether intra-cardiac levels are indeed 
significantly different from peripheral levels. It is difficult to conclude, therefore, that 
any association between raised fibrosis markers and rhythm outcome is necessarily 
due to cardiac fibrosis, as opposed to systemic pathology. 
 
This study was undertaken to compare peripheral levels of four biomarkers of 
fibrosis with intra-cardiac levels, to compare levels in AF patients with matched 
controls, and to compare the levels with left atrial fibrosis, assessed by EP mapping 
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during ablation. The biomarkers chosen were pro-collagen type III N-terminal pro-
peptide (PIIINP), C-telopeptide of type I collagen (ICTP), fibroblast growth factor 23 
(FGF-23) and galectin 3 (gal-3). In order to assess for any AF ʹ specific association 
with these biomarkers, an age- and comorbidity-matched non-AF control group was 
also recruited for comparison. 
Methods 
Participants 
Ethical approval was granted by the National Research Ethics Service Committee ʹ 
Leeds West (ref. 13/YH/0349). Written informed consent was obtained from all 
patients. At a single institution, between September 2014 and August 2015, all 
consecutive patients (n=98) undergoing first-time left atrial ablation for paroxysmal, 
persistent, or long-standing-persistent AF were screened. Patients with systemic 
inflammatory disease, recent or active malignancy, severe kidney disease (eGFR < 30 
ml/min/1.73m2) or collagen disease were excluded, resulting in 95 participants. Two 
participants subsequently decided against ablation and withdrew themselves from 
the study, resulting in a final total of 93 participants in the AF ablation group. 
Recruitment of controls followed recruitment of AF patients. Patients attending 
cardiology clinics for non ʹ AF related conditions were screened and selected to 
create a control group with matched overall population values for age, gender, left 
ventricular ejection fraction and comorbidities. Patients were excluded from the 
control group if they had any previously documented AF or other sustained 
arrhythmia of any cause, undiagnosed palpitations, or no documentation of sinus 
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rhythm. Other control group exclusion criteria were the same as for the AF group. 
 
Echocardiography 
All participants underwent trans-thoracic echocardiography prior to ablation by a 
single operator with over 5 ǇĞĂƌƐ͛ experience. Images were obtained according to 
British Society of Echocardiography standard guidance. Atrial and ventricular volume 
measurements were obtained by ^ŝŵƉƐŽŶ͛Ɛ biplane method from apical 4-chamber 
and 2-chamber views. Antero-posterior left atrial diameter was measured in the 2D 
parasternal long-axis view. All atrial measurements were taken at the end of 
ventricular systole. 
Serum analysis 
Apart from blood sample collection, ablation procedures were carried out according 
to standard techniques. Whole blood was obtained from four sites per patient 
during the ablation procedure, but before any tissue ablation occurred. Femoral vein 
blood was aspirated via the femoral vein sheath. Intra-cardiac blood was aspirated 
via a long sheath placed in the right atrium, coronary sinus and, after trans-septal 
puncture, the left atrium. The first 10ml of aspirate from the sheath or catheter was 
discarded to ensure samples were not contaminated with saline previously used as a 
flush. Blood was transferred to sterile, non-pyrogenic serum separator tubes and 
allowed to clot for between 30 and 60 minutes. Tubes were then immediately 
centrifuged for 15 minutes at rcf x 1600g. Aliquots of the separated serum were then 
transferred to sterile, non-pyrogenic Eppendorf tubes and stored at -70oC until 
analysis. Samples were then thawed prior to analysis, so underwent only one freeze-
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thaw cycle. Blood samples from control patients were obtained from a peripheral 
vein using standard venepuncture equipment. 
 
ELISA 
Target biomarkers were analysed using commercially available enzyme-linked 
immunosorbent assay (ELISA) kits. PIIINP, FGF-23, and gal-3 were analysed using kits 
produced by Elabscience (Beijing, China). ICTP was analysed using kits produced by 
Cusabio Life Science (Wuhan, China). Kits were processed according to the 
ŵĂŶƵĨĂĐƚƵƌĞƌ͛Ɛ instructions. Standards of known concentration and serum samples 
were tested in duplicate. Two wells per plate were used as ͚ďůĂŶŬƐ͛ to allow for 
background correction. Serum concentrations were extrapolated from optical 
density readings using a 4-parameter logistic curve derived from the standards. 
Inter- and intra-assay coefficients of variation were <15%.  Lower limits of detection 
were; ICTP = 25ng/ml, gal-3 = 0.156ng/ml, FGF-23 = 15.625pg/ml, PIIINP = 23.438 
pg/ml. 
Electrophysiological mapping 
Left atrial bipolar voltage maps were taken in all patients, irrespective of rhythm, 
after trans-septal puncture using a circular mapping catheter and either Carto 
(Biosense Webster) or NavX Velocity (St. Jude Medical) EP mapping systems. The 
minimum mapping time window for any electrode position was 2 seconds, in order 
to account for variation in voltage ʹ particularly for those patient in AF during 
mapping. Data from these systems was then exported according to the 
manufacturer͛Ɛ instructions and reformatted to allow analysis on appropriate 
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software according to previously published methods.6 Pulmonary veins, left atrial 
appendage and mitral valve surface were removed from the patient specific atrial 
anatomies generated during clinical mapping. The resulting shell was used to express 
the proportion of endocardial surface area which represented fibrotic LA tissue 
based on a voltage value between 0.2-0.5mV, as a percentage of the overall LA 
endocardial surface (not including the removed structures). Figure 1 shows a 
representative voltage map. 
Statistical analysis 
Values are expressed as either median (interquartile range) for non-normally 
distributed data, or mean ± standard deviation for normally distributed data. A p-
value of ч0.05 was considered significant. Data were tested for normality using the 
Shapiro-Wilks test, and non-parametric data underwent logarithmic or square-root 
transformation if possible. For non-parametric data, comparison was made using 
Mann-Whitney test for independent samples, tŝůĐŽǆŽŶ͛Ɛ signed rank test for 2 
paired samples, or &ƌŝĞĚŵĂŶ͛Ɛ test for 3 or more paired samples. Where &ƌŝĞĚŵĂŶ͛Ɛ 
test was significant, post-hoc Wilcoxon tests were carried out between the groups, 
with Bonferroni significance correction. Correlations were examined using 
^ƉĞĂƌŵĂŶ͛Ɛ coefficient. For assessment of associations between baseline 
characteristics and biomarker levels, univariate linear regression analysis was 
performed, with mean biomarker levels across the sample sites for each participant 
as the dependent variable. Variables which were associated with a significance level 
of p=0.100 or less were then included in multivariate linear regression where the 
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variable data was appropriate for such analysis. Analysis was carried out using SPSS 
version 22 and Minitab version 17. 
Results 
Baseline characteristics and comparison with controls 
Table 1 shows the baseline characteristics and comorbidities present within the 
study population, and comparison between characteristics of AF and control groups. 
There was no significant difference between the groups in age, gender, LV ejection 
fraction, or comorbidity. LA volume (but not diameter) was significantly higher in the 
AF group (p=0.007). There was no significant difference between levels of PIIINP, 
FGF-23 or gal-3 between the groups, however there was a significantly higher level 
of ICTP in the AF group (p=0.007). 
 
Table 2 shows regression analysis of relationships between left atrial biomarker 
values and baseline characteristics within the AF ablation group.  
After multivariate analysis, significant associations were found between body-mass 
index (BMI) and gal-3 (p<0.001), female gender and gal-3 (p<0.001), LV ejection 
fraction and ICTP (p=0.005), cerebrovascular disease and PIIINP (p<0.001), and time 
since AF diagnosis and PIIINP (p=0.003). Note that for LA voltage analysis, values are 
shown separately for patients in sinus rhythm and in AF during EP mapping. There 
were no associations between biomarker levels and LA voltage-defined fibrosis. 
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Comparison between blood sample sites 
Figure 2 illustrates the distributions of individual biomarker values at each site. No 
significant difference was found between any of the sites for FGF-23 or PIIINP. Gal-3 
levels were not available for RA and CS sites, but femoral levels were significantly 
higher than left atrial levels (p=0.001). Femoral ICTP was higher than LA and RA 
(p<0.001 for both), and CS ICTP was higher than LA (p=0.003) and RA (p<0.001). 
There was no significant difference between the atria, or between femoral and CS 
levels. 
 
Discussion 
In this study, our principal findings were that ICTP is higher in AF patients than in 
matched controls, that none of the studied biomarkers were associated with LA 
fibrosis assessed by voltage mapping, and for gal-3 and ICTP, intra-cardiac sampling 
may be necessary to assess their association with intra-cardiac processes.  However, 
intra-cardiac sampling of FGF-23 or PIIINP gives no further information over 
peripheral sampling.  
 
Atrial cardiomyopathy has recently been described expertly by Goette et al. in their 
exhaustive consensus statement.7 Cardiac fibrosis is a hallmark of atrial 
cardiomyopathy and is characterised by an increase in the turnover of extra-cellular 
matrix. This matrix is principally comprised of type I and type III collagen, so PIIINP 
and ICTP are measurable products of this turnover. Both of these biomarkers have 
shown promise in the prediction of rhythm control success.8, 9 Gal-3 has been shown 
to have direct and indirect effect on cardiac fibrosis and has been studied extensively 
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in the context of heart failure, in which it was found to be a relatively sensitive and 
specific marker of ventricular dysfunction, as well as mortality.10-12  
 
FGF-23, principally studied in the context of its action on phosphate homeostasis in 
kidney disease and heart failure, has been associated with AF, increased LV mass, 
and cardiovascular death. 13-15 Results of studies assessing its association with 
incident AF are mixed. 16, 17 It has been shown to be required for cardiomyocyte 
proliferation and differentiation in early embryonic stages and this may be of 
interest in AF, as human cardiomyocytes in vitro have been shown to de-
differentiate to a more primitive cell phenotype in cardiac fibrosis. 18 FGF-23 has 
been associated with increased atrial wall tension as manifest by raised NT-ProBNP 
levels, and it is unclear as to whether it has a direct effect on the atrial wall, or 
increases LA pressure by its effect on LV hypertrophy and fibrosis.  
 
Participants and generalizability  
As far as we are aware, this is the largest study that assesses the relationship 
between peripheral and intra-cardiac biochemical markers of fibrosis in an AF 
ablation population. The study population is representative of patients undergoing 
ablation for AF; despite screening of all 98 consecutive patients listed for AF ablation 
in a 12 month period, only 3 patients were excluded, and 2 withdrew. The results are 
therefore generalizable to the wider population of AF ablation patients.  
 
Amongst the AF patient population as a whole, such patients represent a younger, 
healthier group with fewer comorbidities, with males being over-represented. As 
10 
such, the results may not be as generalizable to AF patient groups beyond those 
suitable for ablation.  As expected, rates of comorbidity (e.g. cerebrovascular disease 
and renal impairment) were low in this population, so conclusions drawn about 
associations between the biomarkers and comorbidities should be drawn with 
caution. 
It should also be noted that there is a large element of scatter amongst the 
biomarker readings as can be seen in figure 2 and the inter-quartile ranges of the 
biomakers. Despite this, however, statistically significant differences between the 
biomarker distributions could still be determined. 
 
Relationship between intra-cardiac and femoral levels 
Peripheral sampling of all four of these biomarkers proportionally represents their 
intra-cardiac levels. In the case of PIIINP and FGF-23, the lack of difference between 
peripheral and intra-cardiac levels suggests that these biomarkers may reflect 
systemic fibrosis (or other non-fibrotic processes in which they are involved). In the 
case of ICTP and gal-3, levels are higher peripherally. Therefore, it cannot be 
concluded that the heart is the main source of these substances in the bloodstream. 
Systemic rather than cardiac pathology may, therefore, be the principal driver 
behind any association between these biomarkers and successful treatment of AF. 
Such findings are in agreement with the study by Okumura et al., which showed no 
difference between intra-cardiac and femoral levels of their chosen inflammation 
and extra-cellular matrix turnover markers (which included ICTP) in 25 ablation 
patients. 8 
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Intra-cardiac differences 
PIIINP and FGF-23 were not significantly different between intra-cardiac sites. 
Therefore, any fibrosis present within the myocardium does not appear to 
contribute to a detectable increase of these compounds in the blood. However, ICTP 
was higher in the CS than either the LA or the RA. This suggests that ICTP enters the 
bloodstream from the myocardium at detectable levels, although, as discussed, this 
is masked in peripheral blood. This finding does not distinguish between ICTP arising 
from the ventricle or the atrium. 
 
Relationship with baseline characteristics 
In this study we found no evidence to support a relationship between the 
biomarkers and simple baseline echocardiographic markers of left atrial remodelling. 
Neither was there any relationship with AF classification, (paroxysmal vs. non-
paroxysmal patients), however PIIINP was associated with duration of AF, measured 
by time since reported clinical diagnosis. PIIINP has been shown to have a complex 
relationship with AF incidence, with mixed results regarding its association with AF 
duration.19 More work is required to understand the role PIIINP may play in relation 
to the temporal progression of the disease. The BMI and gender associations which 
we encountered with gal-3 have been previously described in other patient groups. 
20, 21 A relationship between ICTP and ventricular function has also been described, 
to a much lesser extent. This study was not designed to examine such an association, 
and as only 5 patients had a reduced LVEF, further studies are required. Similarly, 
although an association between PIIINP and cerebrovascular disease was found in 
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this study, this was based on only 5 patients and should be interpreted with 
appropriate caution. 
 
Relationship with LA voltage data 
The presence of low voltage areas within the LA has been shown to be an 
independent predictor of AF recurrence after ablation, and there is evidence that 
these areas of low voltage are associated with fibrosis identified with MRI. 22, 23 
Voltage criteria for identifying such areas are not universally established, however 
studies have addressed the issue. 22, 24 The definition of ͚low voltage͛ in this study 
(0.2-0.5mV) is drawn from these studies. The lower value chosen was 0.2mV rather 
than 0mV to reduce artefact caused by poor contact between the mapping catheter 
and the endocardium. Assuming that this method is a consistent index of LA fibrosis, 
the results suggest that levels of these four biomarkers are not reflective of atrial 
fibrosis. For the biomarkers where there is some prior evidence of predictive value 
of arrhythmia recurrence (PIIINP, ICTP and gal-3), this may reflect their involvement 
in fibrosis elsewhere in the heart (e.g. the LV), or elsewhere in the body. 
 
Implications 
PIIINP and gal-3 levels have been associated with incidence of AF, but their use in the 
prediction of catheter ablation success has yielded mixed results.12, 25, 26 This study 
may help to explain why this is the case, as it suggests that systemic (or at least non-
atrial) factors may have the prominent role in their presence in the circulation, as 
evidenced by the lack of difference in matched controls. If cardiac fibrosis is the 
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critical component determining success in AF ablation, then such markers may have 
limited use in this role.  
 
No studies have addressed the clinical utility of FGF-23 in predicting the success of 
AF ablation, and the findings presented here suggest such utility may be limited. On 
the other hand, ICTP does appear to be involved in local cardiac fibrosis and this may 
help to explain why it has shown more promise. In this study, however, we have 
shown that ICTP does not appear to be significantly associated with LA fibrosis. 
Therefore, it is potentially fibrosis elsewhere within the heart, most likely the LV, 
which the increased CS ICTP levels reflect. 
Conclusion 
ICTP levels are associated with the presence of AF in comparison with non-AF 
controls. PIIINP levels are associated with AF duration. None of ICTP, PIIINP, gal-3 or 
FGF-23 appear to reflect atrial fibrosis when assessed by voltage mapping criteria. 
Intra-cardiac sampling of FGF-23 or PIIINP gives no further information over 
peripheral sampling. For gal-3 and ICTP, intra-cardiac sampling may be necessary to 
assess their association with intra-cardiac processes. 
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Figure 1. Representative left atrial voltage map. Areas in red represent voltage of 0.2-
0.5mV. Pulmonary veins and left atrial appendage were removed prior to analysis. 
 
Figure 2. Individual value plots of biomarker levels at each sample site, with median values. Arrows 
on ICTP plot represent results of post-hoc testing of between-group differences. 
Table 1. Participant characteristics and comparison with non ʹ AF controls 
Characteristic 
Distribution 
P value 
AF Group n= 93 
Control group n = 
36 
Age (years) 56.7 ± 11.9 60.7 ± 9.7) 0.073 
BMI (kg/m2) 29.7 ± 5.1 29.3 ± 5.1 0.679 
Paroxysmal AF 63 (67.7) - - 
Female gender 29 (31.2) 11 (30.1) 0.945 
Hypertension 31 (33.3) 17 (47.2) 0.143 
Diabetes Mellitus 9 (9.7) 5 (13.9) 0.490 
Ischaemic Heart Disease 5 (5.4) 4 (11.1) 0.251 
Chronic Kidney Disease 0 (0.0) 0 (0.0) - 
Cerebrovascular disease  5 (5.4) 5 (13.9) 0.105 
CHA2DS2VASc 
Score
 
 
0 
1 
2 
3 
4 
5 
41 (44.1) 
17 (18.3) 
22 (23.7) 
10 (10.8) 
2 (2.2) 
1 (1.1) 
- - 
AADs*
 
 
Amiodarone 
Flecainide 
Dispoyramide 
Propafenone 
Sotalol 
None 
15 (16.1) 
16 (17.2) 
1 (1.1) 
1 (1.1) 
2 (2.2) 
58 (62.4) 
- - 
Rate-limiting 
drugs 
Beta-blocker 
Ca2+ channel blocker 
Digoxin 
No drug 
1 drug 
2 drugs 
3 drugs 
54 (58.1) 
12 (12.9) 
7 (7.5) 
30 (32.2) 
56 (60.2) 
6 (6.5) 
1 (1.1) 
- - 
Total no. of 
drugs for 
rate/rhythm  
control of AF  
No drug 
1 drug 
2 drugs 
3 drugs 
16 (17.2) 
51 (54.8) 
23 (24.7) 
3 (3.2) 
- - 
LA Volume (ml) 68.0 ± 22.5 56.1 ± 19.4 0.007 
LA Diameter (mm) 40.5 ± 7.0 39.0 ± 5.7 0.263 
Mean LA Pressure (mmHg) 11.0 (9.0) - 
 
Mean RA Pressure (mmHg) 6.0 (6.0) - 
 
LV end-diastolic volume (ml) 107.0 ± 29.6 106.9 ± 31.7 0.993 
LV ejection fraction (%) 59.0 ± 7.1 57.3 ± 13.1 0.464 
PIIINP (pg/ml) 60.8 (66.1) 54.6 (59.65) 0.749 
ICTP (ng/ml) 330.1 (324.1) 221.2 (228.6) 0.007 
FGF-23 (pg/ml) 39.7 (29.9) 37.4 (81.1) 0.334 
Gal-3 (ng/ml) 27.7 (43.12) 22.0 (31.3) 0.323 
Values = mean ± standard deviation, median (IQR) or frequency (%) as appropriate. AAD = 
anti-arrhythmic drug. BSA = body surface area. *No patients were on >1 AAD 
  
 
 
 
 
 
Table 2 Univariate and multivariate analysis of association between participant 
characteristics and biomarker levels 
Characteristic PIIINP ICTP FGF-23 Gal-3 
 Beta P Beta p Beta p Beta p 
Age (years) 
0.033 0.838 -0.122 0.306 -0.188 0.339 0.211 
0.105 
0.059 
0.139 
BMI (kg/m2) 
0.043 0.789 0.112 0.344 
-0.377 
-0.321 
0.048 
 0.063 
0.429 
0.461 
0.000 
 <0.001 
Paroxysmal AF 
0.078 0.625 0.047 0.692 
0.399 
0.210 
0.035 
 0.243 
-0.017 0.877 
Time since AF 
diagnosis 
0.343 
0.389 
0.020 
0.003 
-0.062 0.610 -0.004 0.984 -0.161 0.873 
Female gender 
0.248  
-0.032 
0.114  
0.799 
-0.107 0.370 -0.214 0.274 
0.484 
0.503 
0.000 
 <0.001 
Hypertension 
0.172 0.277 -0.062 0.602 -0.053 0.789 0.095 0.397 
Diabetes Mellitus 
0.018 0.908 
-0.184 
-0.171 
0.120  
0.166 
-0.054 0.787 0.084 0.458 
Ischaemic Heart 
Disease 
0.285 
0.097 
0.068 
 0.449 
0.090 0.450 -0.025 0.898 -0.020 0.861 
Myocardial infarction 
- - - - 
Chronic Kidney 
Disease 
- - - - 
Cerebrovascular 
disease  
0.313 
 0.511 
0.044 
<0.001 
-0.024 0.838 -0.289 0.136 -0.064 0.567 
CHA2DS2VASc Score 
0.106 0.468 
-0.197 
-0.037 
0.079 
0.775 
-0.197 0.315 
0.245 
0.354 
0.028 
0.724 
Number of AF drugs 
-0.061 0.677 -0.041 0.720 0.148 0.452 0.045 0.693 
LA Volume / BSA 
(ml/m2) 0.066 0.691 -0.105 0.397 
-0.431 
-0.295 
0.032 
 0.103 
-0.098 0.404 
LA Diameter / BSA 
(mm/m2) 
0.185 0.252 -0.068 0.584 -0.327 0.103 -0.033 0.782 
Mean LA Pressure 
(mmHg) 0.032 0.844 0.067 0.580 -0.302 0.126 
0.209 
0.086 
0.067 
 0.335 
Mean RA Pressure 
(mmHg) 0.031 0.851 -0.087 0.466 
-0.462 
-0.295 
0.015 
0.077 
0.136 0.241 
LV end-diastolic 
volume / BSA 
(ml/m2) 
0.102 
 
0.573 
 
0.005 
 
0.967 
 
-0.066 
 
0.771 
 
-0.098 
 
0.404 
 
LV ejection fraction 
% 0.140 0.431 
-0.325 
-0.339 
0.001  
0.012 
-0.050 0.827 0.035 0.778 
LA voltage (% 0.2-
0.5mV) (SR n=60) 0.364 0.080 0.003 0.988 0.104 0.761 0.080 0.652 
LA voltage (% 0.2-
0.5mV) (AF n=33) 0.171 0.867 -0.409 0.073 -0.576 0.135 0.311 0.131 
 Italics = results of multivariate analysis. Bold italics = significant association after multivariate 
analysis. 
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